Relay Therapeutics (RLAY) to Release Earnings on Thursday

Relay Therapeutics (NASDAQ:RLAYGet Rating) is scheduled to be issuing its quarterly earnings data after the market closes on Thursday, May 5th. Analysts expect the company to announce earnings of ($0.63) per share for the quarter.

Relay Therapeutics (NASDAQ:RLAYGet Rating) last announced its earnings results on Thursday, February 24th. The company reported $0.36 EPS for the quarter, beating the consensus estimate of ($0.60) by $0.96. The business had revenue of $0.57 million for the quarter. Relay Therapeutics had a negative return on equity of 36.49% and a negative net margin of 12,012.94%. On average, analysts expect Relay Therapeutics to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Shares of NASDAQ:RLAY opened at $25.33 on Friday. The company has a market cap of $2.75 billion, a P/E ratio of -6.58 and a beta of 1.66. Relay Therapeutics has a one year low of $19.05 and a one year high of $38.60. The business’s 50-day simple moving average is $27.07 and its 200 day simple moving average is $28.23.

In other news, insider Donald A. Bergstrom sold 22,994 shares of Relay Therapeutics stock in a transaction that occurred on Tuesday, February 22nd. The stock was sold at an average price of $20.94, for a total value of $481,494.36. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Donald A. Bergstrom sold 8,000 shares of the business’s stock in a transaction that occurred on Tuesday, March 1st. The shares were sold at an average price of $23.88, for a total value of $191,040.00. The disclosure for this sale can be found here. In the last quarter, insiders sold 110,856 shares of company stock valued at $3,078,679. Insiders own 4.88% of the company’s stock.

A number of large investors have recently added to or reduced their stakes in RLAY. BlackRock Inc. boosted its position in Relay Therapeutics by 12.0% during the 4th quarter. BlackRock Inc. now owns 5,993,613 shares of the company’s stock valued at $184,062,000 after purchasing an additional 641,001 shares during the period. Goldman Sachs Group Inc. boosted its position in Relay Therapeutics by 177.6% during the 4th quarter. Goldman Sachs Group Inc. now owns 443,001 shares of the company’s stock valued at $13,604,000 after purchasing an additional 283,420 shares during the period. Morgan Stanley boosted its position in Relay Therapeutics by 16.1% during the 2nd quarter. Morgan Stanley now owns 569,645 shares of the company’s stock valued at $20,843,000 after purchasing an additional 79,037 shares during the period. Bank of New York Mellon Corp boosted its position in Relay Therapeutics by 40.3% during the 3rd quarter. Bank of New York Mellon Corp now owns 234,882 shares of the company’s stock valued at $7,406,000 after purchasing an additional 67,509 shares during the period. Finally, Deutsche Bank AG boosted its position in Relay Therapeutics by 134.1% during the 4th quarter. Deutsche Bank AG now owns 100,218 shares of the company’s stock valued at $3,077,000 after purchasing an additional 57,417 shares during the period. Institutional investors and hedge funds own 83.43% of the company’s stock.

Several research firms have issued reports on RLAY. Berenberg Bank began coverage on Relay Therapeutics in a report on Tuesday, February 1st. They set a “buy” rating and a $45.00 price objective on the stock. Guggenheim dropped their price objective on Relay Therapeutics from $52.00 to $45.00 in a report on Monday, January 3rd. Finally, Zacks Investment Research upgraded Relay Therapeutics from a “hold” rating to a “buy” rating and set a $31.00 price objective on the stock in a report on Thursday. Six analysts have rated the stock with a buy rating, According to data from MarketBeat, Relay Therapeutics currently has an average rating of “Buy” and a consensus price target of $46.57.

Relay Therapeutics Company Profile (Get Rating)

Relay Therapeutics, Inc operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and RLY-1971, an oral small molecule inhibitor of protein tyrosine phosphatase Src homology region 2 domain-containing phosphatase-2 that is in Phase 1 trial in patients with advanced solid tumors.

See Also

Earnings History for Relay Therapeutics (NASDAQ:RLAY)

Receive News & Ratings for Relay Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Relay Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.